Vamil Divan
Stock Analyst at Guggenheim
(4.89)
# 62
Out of 5,112 analysts
244
Total ratings
69.71%
Success rate
23.22%
Average return
Main Sectors:
Stocks Rated by Vamil Divan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintains: Buy | $230 → $221 | $198.46 | +11.36% | 8 | Dec 18, 2025 | |
| JNJ Johnson & Johnson | Maintains: Buy | $206 → $227 | $210.33 | +7.93% | 18 | Dec 5, 2025 | |
| PFE Pfizer | Maintains: Buy | $33 → $35 | $25.04 | +39.78% | 23 | Nov 24, 2025 | |
| JBIO Jade Biosciences | Maintains: Buy | $14 → $17 | $15.68 | +8.42% | 2 | Nov 18, 2025 | |
| ELDN Eledon Pharmaceuticals | Maintains: Buy | $9 → $8 | $1.57 | +409.55% | 1 | Nov 18, 2025 | |
| ANIP ANI Pharmaceuticals | Maintains: Buy | $114 → $115 | $82.35 | +39.65% | 13 | Nov 10, 2025 | |
| SCYX SCYNEXIS | Maintains: Buy | $4 → $3 | $0.63 | +376.27% | 3 | Oct 28, 2025 | |
| ABBV AbbVie | Maintains: Buy | $227 → $242 | $224.31 | +7.89% | 28 | Oct 20, 2025 | |
| SVRA Savara | Maintains: Buy | $8 → $11 | $6.11 | +80.03% | 2 | Sep 9, 2025 | |
| VALN Valneva SE | Maintains: Buy | $14 → $13 | $8.24 | +57.77% | 2 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $39 | $32.58 | +19.71% | 2 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $7 | $2.35 | +197.87% | 2 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $288 | $326.01 | -11.66% | 1 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $5.45 | +1,000.92% | 1 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $115 | $99.18 | +15.95% | 14 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $47 | $33.89 | +38.68% | 8 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $3.39 | +194.99% | 3 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $59 → $61 | $48.53 | +25.70% | 5 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $20.83 | - | 5 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $26 | $4.01 | +548.38% | 2 | Jun 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $3.57 | - | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $19 | $26.93 | -29.45% | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $95 → $98 | $141.70 | -30.84% | 8 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $34 | $28.04 | +21.26% | 13 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $2.33 | +329.18% | 3 | May 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $49 | $148.00 | -66.89% | 3 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $315 → $356 | $1,041.79 | -65.83% | 17 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $6 | $6.99 | -14.16% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $144 → $154 | $10.87 | +1,316.74% | 9 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 | $7.08 | +111.86% | 5 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $31.53 | - | 6 | Dec 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | n/a | $30.06 | - | 13 | Jul 10, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $15 | $7.84 | +91.33% | 4 | Aug 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $58 → $61 | $53.55 | +13.91% | 8 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $103 | $3.65 | +2,721.92% | 3 | Jan 17, 2018 |
Insmed
Dec 18, 2025
Maintains: Buy
Price Target: $230 → $221
Current: $198.46
Upside: +11.36%
Johnson & Johnson
Dec 5, 2025
Maintains: Buy
Price Target: $206 → $227
Current: $210.33
Upside: +7.93%
Pfizer
Nov 24, 2025
Maintains: Buy
Price Target: $33 → $35
Current: $25.04
Upside: +39.78%
Jade Biosciences
Nov 18, 2025
Maintains: Buy
Price Target: $14 → $17
Current: $15.68
Upside: +8.42%
Eledon Pharmaceuticals
Nov 18, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $1.57
Upside: +409.55%
ANI Pharmaceuticals
Nov 10, 2025
Maintains: Buy
Price Target: $114 → $115
Current: $82.35
Upside: +39.65%
SCYNEXIS
Oct 28, 2025
Maintains: Buy
Price Target: $4 → $3
Current: $0.63
Upside: +376.27%
AbbVie
Oct 20, 2025
Maintains: Buy
Price Target: $227 → $242
Current: $224.31
Upside: +7.89%
Savara
Sep 9, 2025
Maintains: Buy
Price Target: $8 → $11
Current: $6.11
Upside: +80.03%
Valneva SE
Sep 8, 2025
Maintains: Buy
Price Target: $14 → $13
Current: $8.24
Upside: +57.77%
Sep 8, 2025
Maintains: Buy
Price Target: $31 → $39
Current: $32.58
Upside: +19.71%
Jul 14, 2025
Maintains: Buy
Price Target: $6 → $7
Current: $2.35
Upside: +197.87%
May 20, 2025
Assumes: Neutral
Price Target: $288
Current: $326.01
Upside: -11.66%
Apr 21, 2025
Initiates: Buy
Price Target: $60
Current: $5.45
Upside: +1,000.92%
Apr 17, 2025
Reiterates: Buy
Price Target: $115
Current: $99.18
Upside: +15.95%
Apr 14, 2025
Reiterates: Buy
Price Target: $47
Current: $33.89
Upside: +38.68%
Mar 20, 2025
Reiterates: Buy
Price Target: $10
Current: $3.39
Upside: +194.99%
Feb 27, 2025
Maintains: Buy
Price Target: $59 → $61
Current: $48.53
Upside: +25.70%
Jan 17, 2025
Reiterates: Neutral
Price Target: n/a
Current: $20.83
Upside: -
Jun 15, 2023
Reiterates: Buy
Price Target: $26
Current: $4.01
Upside: +548.38%
Mar 1, 2023
Initiates: Neutral
Price Target: n/a
Current: $3.57
Upside: -
Aug 10, 2022
Maintains: Neutral
Price Target: $27 → $19
Current: $26.93
Upside: -29.45%
Aug 8, 2022
Maintains: Neutral
Price Target: $95 → $98
Current: $141.70
Upside: -30.84%
Jul 28, 2022
Maintains: Buy
Price Target: $36 → $34
Current: $28.04
Upside: +21.26%
May 25, 2022
Maintains: Buy
Price Target: $20 → $10
Current: $2.33
Upside: +329.18%
May 3, 2022
Maintains: Buy
Price Target: $51 → $49
Current: $148.00
Upside: -66.89%
May 2, 2022
Maintains: Buy
Price Target: $315 → $356
Current: $1,041.79
Upside: -65.83%
Mar 16, 2022
Maintains: Buy
Price Target: $8 → $6
Current: $6.99
Upside: -14.16%
Mar 3, 2022
Maintains: Buy
Price Target: $144 → $154
Current: $10.87
Upside: +1,316.74%
May 6, 2021
Upgrades: Buy
Price Target: $15
Current: $7.08
Upside: +111.86%
Dec 13, 2019
Downgrades: Neutral
Price Target: n/a
Current: $31.53
Upside: -
Jul 10, 2019
Assumes: Neutral
Price Target: n/a
Current: $30.06
Upside: -
Aug 15, 2018
Assumes: Outperform
Price Target: $15
Current: $7.84
Upside: +91.33%
Jul 27, 2018
Maintains: Neutral
Price Target: $58 → $61
Current: $53.55
Upside: +13.91%
Jan 17, 2018
Initiates: Outperform
Price Target: $103
Current: $3.65
Upside: +2,721.92%